107results about How to "High therapeutic effect" patented technology

Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.

A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and / or substitution of at least one amino acid in the constant region to reduce the ADCC and / or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and / or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.

Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.

A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ω3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.

An M toxin of type A botulinum toxin (HA-negative substance) and a mixture of L toxin and LL toxin (HA-positive substance) are compared and examined in inhibitory action for neuromuscular transmission and therapeutic index. As a result, it is found that M toxin of type A botulinum toxin has characteristics of: 1) having an excellent inhibitory action for neuromuscular transmission; 2)showing a high therapeutic index; 3) showing a low antigenicity and 4) suffering from little reduction in efficacy even after repeatedly administered, compared with the mixture of L toxin and LL toxin. Owing to these characterics, the M toxin of type A botulinum toxin is particularly useful as a therapeutic agent for diseases caused by hypermyotonia such as strabismus, blepharospasm, facial spasms, spasmodic torticollis, paralysis after cerebral apoplexy, infantile cerebral paralysis, spasmodic phonopathy, headache such as migraine, chronic pain such as lumbago, stiff shoulder, muscular relaxation disorder accompanied with onset of Parkinson's disease or multiple sclerosis, myofascial pain syndrome, masticatory spasm, chronic anal fissure, urinary inconsistency, grinding of teeth, facial myokymia, tic, topical dystonia and wrinkles.

A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided. That is, the present invention provides the immunostimulatory oligonucleotide composed of a base sequence represented by a formula: 5′-(G)MPXCGYQ(G)N-3′ (SEQ ID NO: 118) (X and Y are mutually independent and represent an arbitrary sequence which has a length of 0 to 10 nucleotides and does not contain 4 or more consecutive G residues, and a length of X+Y is 6 to 20 nucleotides; XCGY contains a palindrome sequence having a length of at least 8 nucleotides and has a length of 8 to 22 nucleotides; P and Q are mutually independent and represent one nucleotide other than G; M represents an integer of 6 to 10 and N represents an integer of 0 to 3) wherein a full length thereof is 16 to 37 nucleotides (except for an oligonucleotide composed of a base sequence represented by SEQ ID NO:5), the pharmaceutical application thereof.

Provided is a radiotherapeutic agent, including a composite particle, which is obtained by binding a molecule that specifically recognizes a target to a substrate particle including titanium peroxide, and which generates reactive oxygen through irradiation with a radiation. Further, because the radiotherapeutic agent contains the molecule that specifically recognizes a target, the radiotherapeutic agent has a function of accumulating in the target. The radiotherapeutic agent is capable of enhancing effects of radiotherapy, and is capable of reducing side effects on a living body to efficiently attack the target.

Disclosed herein are compositions and methods for the delivery and targeting of therapeutics using nanometer sized polysaccharide structures. The methods and compositions described herein afford improved efficacy for pharmaceuticals such as anti-tumor drugs on metastatic tumor. The methods described herein are applicable to all chemotherapeutic agents and are especially useful for poorly soluble (hydrophobic) drugs which when formulated with the present compositions render them deliverable in physiological fluids. The methods and compositions described herein also improve the efficacy of pharmaceutical agents by targeting carbohydrate receptors specific to tumors that mediate endocytosis or enhance delivery of the drug to the ultimate site of action.

Technical Field: TeaTechnical Problem: To provide a drinkable tea having a high therapeutic effect against atopic dermatitis.Means for Solving: It is characterized in that it contains extracts drawn from one, two or more medicinal herbs selected from the group consisting of Lightyellow Sophora Root, Isatis Leaf, and Terminalia Fruit. Atopic dermatitis can be cured by improving allergic constitution from the inside of body owing to antibacterial effect and antiviral effect of Lightyellow Sophora Root, Isatis Leaf and Terminalia Fruit, antiallergic effect of Lightyellow Sophora Root and Isatis Leaf, and intestinal mucosal protecting effect of Terminalia Fruit, or by a synergistic effect of them.In addition, the pharmacological effect in said extracts drawn from plants is enhanced, a pharmacological effects lacking in said extracts drawn from plants are added, or easiness of drinking the tea as a drinkable drug is improved and thus the therapeutic effect is improved by adding one, two or more auxiliary materials selected from the group of Japanese Angelica Root, Oldenlandia diffusa, Smilax Glarba, Dried Tangerine Peel, Wild Chrysanthemum Flower, Corydalis, Peppermint, Baikal Skullcap, Lithospermum, Kudingcha, Smartweed, and Licorice to the extracts drawn from plants.Principal Use: It is used for the therapy of dermatitis, particularly of atopic dermatitis.

TECHNICAL FIELD: Lotion for therapy of dermatitis TECHNICAL PROBLEM: To provide a lotion for therapy effective against atopic dermatitis. MEANS FOR SOLVING: It has a composition: Lightyellow Sophora Root, 3%; Turmeric, 2%; Magnolia Bark, 2%; Moutan Bark, 2%; Isatis Leaf, 1%; Borneo Camphor Tree (Dryobalanops aromatica Gaertn.f.), 1%; Amur Cork Tree, 2%; Angelicae Dahuricae Root, 1%; Lemon, 3%; Smartweed, 2%; Licorice, 0.5%; Cnidii Rhizoma, 0.5%; Japanese Angelica Root, 0.5%; salicylic acid, 0.5%; resorcinol, 0.5%; alcohol, 30%; and water, 48.5%. A significant therapeutic effect against atopic dermatitis is obtained by a synergistic effect between antibacterial, antiviral, antiallergic, antiphlogistic, and blood-circulation accelerating actions as pharmacological effects of Lightyellow Sophora Root, Turmeric, Magnolia Bark, Moutan Bark, Isatis Leaf, Borneo Camphor Tree (Dryobalanops aromatica Gaertn.f.), Amur Cork Tree, Angelicae Dahurikae Root, Lemon, Smartweed, and Licorice, accelerating action for skin permeation and antifungal-sterilizing action of Cnidii Rhizoma and Japanese Angelicae Root, accelerating action for keratinization and antifungal-sterilizing action of salicylic acid and resorcinol, as described above. Principal Use: It is used for the therapy of dermatitis, particularly of atopic dermatitis.

A radiation irradiation device is provided that includes: a metal target that emits bremsstrahlung X-rays as a radiation beam due to irradiation with an electron beam; a radiation shielding member that includes a slit-shaped radiation passage portion and that is disposed downstream of the metal target in the radiation beam emission direction and is disposed such that a portion of the radiation beam passes through the radiation passage portion and the radiation beam incident to regions other than the radiation passage portion is blocked; and an electron beam generating device that irradiates, onto the metal target, an electron beam such that a diameter at a generation point of the emitted radiation beam is smaller than a length of an entry portion of the radiation passage portion along a length direction of the entry portion.

The invention relates a pharmaceutical composition containing botulinum toxin and a mucopolysaccharide uses thereof with increased pharmacological activity and long lasting botulinum toxin effect.

[Problems] To provide a novel use of multipotential stem cells originating in a fat tissue.[Means for Solving Problems] It is intended to provide a cell preparation which contains multipotential stem cells originating in a fat tissue and is usable for an ischemic disease, impairment of renal function, wound, urinary incontinence or osteoporosis. As the multipotential stem cells originating in a fat tissue, use is made of cells which proliferate in the case of centrifuging cells separated from a fat tissue and culturing the thus sedimented cells (an SVF fraction) under low-serum conditions. In an embodiment, a cell preparation containing the SVF fraction is provided.

TECHNICAL FIELD: Lotion for therapy of dermatitisTECHNICAL PROBLEM: To provide a lotion for therapy effective against atopic dermatitis.MEANS FOR SOLVING: It has a composition: Lightyellow Sophora Root, 3%; Turmeric, 2%; Magnolia Bark, 2%; Moutan Bark, 2%; Isatis Leaf, 1%; Borneo Camphor Tree (Dryobalanops aromatica Gaertn.f.), 1%; Amur Cork Tree, 2%; Angelicae Dahuricae Root, 1%; Lemon, 3%; Smartweed, 2%; Licorice, 0.5%; Cnidii Rhizoma, 0.5%; Japanese Angelica Root, 0.5%; salicylic acid, 0.5%; resorcinol, 0.5%; alcohol, 30%; and water, 48.5%.A significant therapeutic effect against atopic dermatitis is obtained by a synergistic effect between antibacterial, antiviral, antiallergic, antiphlogistic, and blood-circulation accelerating actions as pharmacological effects of Lightyellow Sophora Root, Turmeric, Magnolia Bark, Moutan Bark, Isatis Leaf, Borneo Camphor Tree (Dryobalanops aromatica Gaertn.f.), Amur Cork Tree, Angelicae Dahurikae Root, Lemon, Smartweed, and Licorice, accelerating action for skin permeation and antifungal-sterilizing action of Cnidii Rhizoma and Japanese Angelicae Root, accelerating action for keratinization and antifungal-sterilizing action of salicylic acid and resorcinol, as described above.Principal Use: It is used for the therapy of dermatitis, particularly of atopic dermatitis.

The present invention intended to provide an artificial polyclonal immunoglobulin composition having a high therapeutic effect and high safety, and being capable of stable supply in a large amount. Specifically provided is an artificial polyclonal immunoglobulin composition containing, as active ingredients, 204 polypeptides represented by amino acid sequences set forth in SEQ ID NOS: 1 to 204 of the sequence listing, the polypeptides being plural kinds of single chain variable fragments (also referred to as ScFvs) each comprised of a heavy chain variable region, heavy chain constant region 1, and hinge region (VH-CH1-hinge) of an immunoglobulin, in which the heavy chain variable regions are different each other.

Disclosed is an agent for prevention or treatment of iron overload disorders, comprising 22β-methoxyolean-12-ene-3β,24(4β)-diol or a pharmacologically acceptable salt thereof.

An object of the present invention is to provide a combination drug that has remarkably excellent preventive and / or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and / or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.

Disclosed is a recombinant human adenovirus type 5 adenovirus construct, in which a 920-946 nt sequence of ADV5 genome and a 28532-29360 nt sequence of the E3 region are deleted while a foreign cDNA fragment is reversely inserted into the deleted E3 region. A method for preparing the recombinant ADV5 construct is also provided. The construct provided herein presents a tumor-specific replication, tumor-specific expression of the inserted anti-gene and tumor-specific bystander effects, and is suitable for use in tumor therapy.

The present invention is intended to provide an artificial polyclonal immunoglobulin composition or artificial immunoglobulin fragment composition having a high therapeutic effect and high safety, and being capable of stable supply in a large amount. Specifically provided is an artificial polyclonal immunoglobulin composition containing, as active ingredients, 204 polypeptides represented by amino acid sequences set forth in SEQ ID NOS: 1 to 204 of the sequence listing, the polypeptides being plural kinds of single chain variable fragments (also referred to as ScFvs) each comprised of a heavy chain variable region, heavy chain constant region 1, and hinge region (VH-CH1-hinge) of an immunoglobulin, in which the heavy chain variable regions are different each other. An artificial immunoglobulin fragment composition is also provided that can include at least one polypeptide comprising an amino acid sequence set forth in SEQ ID NOS: 1 to 204, for example, SEQ ID NO. 31.

This invention provides a therapeutic agent for arthrosis exerting inhibitory effects on articular cartilage destruction and high therapeutic effects on arthrosis. The invention provides a therapeutic agent for arthrosis which comprises, as an active ingredient, cyclic phosphatidic acid or carbacyclic phosphatidic acid.

A cancer therapeutic agent according to an embodiment of the present invention contains, as active ingredients, IL-18 and one or more antibodies selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, an anti-CD33 antibody, and an anti-CD52 antibody.

This invention provides a therapeutic agent for arthrosis exerting inhibitory effects on articular cartilage destruction and high therapeutic effects on arthrosis. The invention provides a therapeutic agent for arthrosis which comprises, as an active ingredient, cyclic phosphatidic acid or carbacyclic phosphatidic acid.

The invention provides an M1 type MAP (macrophage activation peptide) and IL-2 (interleukin-2) fusion protein and fusion gene as well as an expression vector and a construction method of the expression vector. The amino acid sequence of the fusion protein is shown as SEQ ID NO:1. A multi-expression M1 type MAP and an IL-2 gene are adopted for splicing coexpression and constitute key factors for activating immune response. The fusion protein can perform a function and play a role simultaneously in intestinal mucosa and mesenteric lymph nodes and has remarkable treatment and regulation functions on PRRSV and PCV2, the quantity of M2 type macrophages is reduced by stimulating proliferation and activation of M1 type macrophages, and immunosuppression is recovered effectively.

A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD+, or a substance involved in the metabolism of any of these substances.

In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.

Disclosed are chelating agent-conjugated α-MSH peptide derivatives, preparation methods thereof, and compositions for use in a diagnosis or treatment of a melanoma tumor containing the same as an active ingredient. The novel α-MSH peptide derivatives conjugated with chelating agent according to the present invention are highly selective to the melanocortin-1 receptor which is α-MSH receptor expressing in melanoma tumor and their labeling rate of a radioactive isotope is high. Also, they remain in kidney shortly and have high taking rate of the melanoma tumor. Therefore, with the aforesaid reasons, they may be effectively used for early diagnosis or treatment of melanoma tumor.

A pharmaceutical composition for therapy of coronary artery narrowing or blockage, which comprises a sustained release preparation containing an angiogenesis factor or a gene encoding the same and a gelatin hydrogel is disclosed. Examples of the angiogenesis factor which may be used include e.g., bFGF and other FGFs, VEGF, HGF, PDGF, TGF, angiopoietin, HIF, cytokine, chemokine, adrenomeduline and the like.

To provide a marker for determining sensitivity of a patient to an anti-cancer agent, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker.The marker for determining the sensitivity of a subject to an anti-cancer agent including oxaliplatin or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker containing one or more genes selected from the group consisting of ALAD gene, C20orf43 gene, CABLES1 gene, CDC14B gene, GDA gene, HOXB6 gene, RPL7AP27 gene, TMEM18 gene, and UGT2B10 gene.

Provided are: a novel compound having a structure different from that of existing drugs; a novel microorganism capable of producing the novel compound; and further; a novel compound effective to a multiple-drug-resistant bacterium. To provide a novel compound having a high therapeutic effect which can be expected to have a low hurdle for practical realization by selecting an intended compound from many candidate compounds based not only on an antibacterial activity but also on evaluation including a therapeutic effect, a cyclic peptide compound shown by the following formula (1) or a pharmaceutically allowable salt thereof and a microorganism with Accession No. NITE BP-870 or a microorganism mutated naturally or artificially therefrom are provided.(In the formula (1), R1 represents an acyl group having 7, 8, or 9 carbon atoms and optionally containing a substituent group; R2 represents a methyl group or a hydrogen atom; and R3 represents an ethyl group or a methyl group.)

An antibacterial agent comprising a compound represented by the following general formula (I), which can exhibit potent antibacterial activity against bacteria that have acquired resistance to quinolones (in the formula, R1 and R4 represents hydrogen atom, hydroxyl group, or a lower alkoxy group; R2 and R3 represents hydrogen atom or hydroxyl group; W represents hydrogen atom, a lower cyclic alkyl group, or a lower alkoxy group; R1′ and R5′ represents hydrogen atom; R2′ and R3′ represents hydrogen atom, hydroxyl group, or a lower alkoxy group; and R4′ represents hydrogen atom or hydroxyl group).